Search

Your search keyword '"M.R. Mirza"' showing total 17 results
Start Over Author "M.R. Mirza"
17 results on '"M.R. Mirza"'

1. VP2-2023: Dostarlimab+chemotherapy for the treatment of primary advanced or recurrent (A/R) endometrial cancer (EC): A placebo (PBO)-controlled randomised phase III trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)

Author

M.R. Mirza, D. Chase, B.M. Slomovitz, R.D. Christensen, Z. Novák, D. Black, L. Gilbert, S. Sharma, G. Valabrega, L.M. Landrum, L.C. Hanker, A. Stuckey, I.A. Boere, M. Gold, S.E. Gill, B.J. Monk, Z. He, S. Stevens, R.L. Coleman, and M.A. Powell

Subjects
Oncology, Hematology
Published
2023

2. VP2-2022: Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer

Author

I.B. Vergote, A. Pérez Fidalgo, E. Hamilton, G. Valabrega, T. Van Gorp, J. Sehouli, D. Cibula, T. Levy, S. Welch, D.L. Richardson, E.M. Guerra Alía, G. Scambia, S. Henry, P. Wimberger, D. Miller, J. Martínez, B.J. Monk, S. Shacham, M.R. Mirza, and V. Makker

Subjects
Oncology, Hematology
Published
2022

5. 33O PRIMA/ENGOT-OV26/GOG-3012 study: Long-term conditional PFS

Author

A.J. Gonzalez Martin, B. Pothuri, I.B. Vergote, W. Graybill, M.R. Mirza, C. McCormick, D. Lorusso, G. Freyer, F. Backes, F. Heitz, A. Redondo Sanchez, R. Moore, C. Vulsteke, R.E. O'Cearbhaill, I. Malinowska, L. Shtessel, W. York, and B.J. Monk

Subjects
Cancer Research, Oncology
Published
2023

6. 35O Overall survival of niraparib with individualized starting dose as maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer adjusted for subsequent PARPi use in placebo group: Results from an ad hoc interim analysis for the phase III NORA study

Author

X. Wu, J. Zhu, R. Yin, J. Yang, J. Liu, J. Wang, L. Wu, Z. Liu, Y. Gao, D. Wang, G. Lou, H. Yang, Q. Zhou, B. Kong, Y. Huang, X. Zhen, J. Dong, C. Zhang, J. Hou, and M.R. Mirza

Subjects
Cancer Research, Oncology
Published
2023

9. 548P Progression-free survival (PFS) and overall survival (OS) in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability–high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC) treated with dostarlimab in the GARNET study

Author

A.V. Tinker, B. Pothuri, L. Gilbert, R. Sabatier, J. Brown, S. Ghamande, C. Mathews, D. O'Malley, V. Boni, A. Gravina, S. Banerjee, R. Miller, J. Pikiel, M.R. Mirza, T. Duan, G. Antony, S. Zildjian, E. Zografos, J. Veneris, and A. Oaknin

Subjects
Oncology, Hematology
Published
2022

10. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer

Author

I. Vergote, A. González-Martín, I. Ray-Coquard, P. Harter, N. Colombo, P. Pujol, D. Lorusso, M.R. Mirza, B. Brasiuniene, R. Madry, J.D. Brenton, M.G.E.M. Ausems, R. Büttner, D. Lambrechts, M. Ausems, J. Brenton, M. Abreu, S. Balboni, S. Banerjee, M. Barberis, M.P. Barretina Ginesta, J.-F. Baurain, M. Bignami, L. Bjorge, P. Blecharz, I. Bruchim, M. Capilna, N. Cerana, A. Cicchetti, D. Collins, N. Concin, M. D’Incalci, B. Davidson, T. de la Motte Rouge, P. De Iaco, F. Demirkiran, H. Denys, T. Doerk, A. Dorum, A. Ferrero, A.P. Fidalgo, M. Genuardi, L. Gladieff, R. Glasspool, C. Grimm, M. Gultekin, E. Hahnen, A. Hasenburg, A. Hegmane, V. Heinzelmann, E. Hogdall, R. Janavicius, S. Jarmalaite, R. Kalachand, R. Kaneva, S. Kilickap, R. Kocian, D. Kolencik, R. Kristeleit, A. Kryzhanivska, A. Leary, B. Lemley, M. Ligtenberg, J.A. López-Guerrero, C.J. Lord, E. Avall-Lundqvist, J. Maenpaa, S. Mahner, F. Marmé, C. Marth, I. McNeish, S. Merkelbach-Bruse, M. Mourits, N. Normanno, A. Oaknin, K. Ojamaa, C. Papdimitriou, F. Penault-Llorca, A.M. Perrone, S. Pignata, E. Pikarsky, E. Rouleau, M. Rubio, A. Sapino, B. Schmalfeldt, J. Sehouli, R. Shapira, K.D. Steffensen, V. Sukhin, J. Syrios, Z. Szallasi, C. Taskiran, M. Terzic, M. Tischkowitz, I. Toth, K. Van de Vijver, M.A. Vardar, B. Wasag, P. Wimberger, E. Witteveen, Vergote I., Gonzalez-Martin A., Ray-Coquard I., Harter P., Colombo N., Pujol P., Lorusso D., Mirza M.R., Brasiuniene B., Madry R., Brenton J.D., Ausems M.G.E.M., Buttner R., Lambrechts D., Ausems M., Brenton J., Abreu M., Balboni S., Banerjee S., Barberis M., Barretina Ginesta M.P., Baurain J.-F., Bignami M., Bjorge L., Blecharz P., Bruchim I., Capilna M., Cerana N., Cicchetti A., Collins D., Concin N., D'Incalci M., Davidson B., de la Motte Rouge T., De Iaco P., Demirkiran F., Denys H., Doerk T., Dorum A., Ferrero A., Fidalgo A.P., Genuardi M., Gladieff L., Glasspool R., Grimm C., Gultekin M., Hahnen E., Hasenburg A., Hegmane A., Heinzelmann V., Hogdall E., Janavicius R., Jarmalaite S., Kalachand R., Kaneva R., Kilickap S., Kocian R., Kolencik D., Kristeleit R., Kryzhanivska A., Leary A., Lemley B., Ligtenberg M., Lopez-Guerrero J.A., Lord C.J., Avall-Lundqvist E., Maenpaa J., Mahner S., Marme F., Marth C., McNeish I., Merkelbach-Bruse S., Mourits M., Normanno N., Oaknin A., Ojamaa K., Papdimitriou C., Penault-Llorca F., Perrone A.M., Pignata S., Pikarsky E., Rouleau E., Rubio M., Sapino A., Schmalfeldt B., Sehouli J., Shapira R., Steffensen K.D., Sukhin V., Syrios J., Szallasi Z., Taskiran C., Terzic M., Tischkowitz M., Toth I., Van de Vijver K., Vardar M.A., Wasag B., Wimberger P., Witteveen E., Vergote, I, Gonzalez-Martin, A, Ray-Coquard, I, Harter, P, Colombo, N, Pujol, P, Lorusso, D, Mirza, M, Brasiuniene, B, Madry, R, Brenton, J, Ausems, M, Buttner, R, Lambrechts, D, Abreu, M, Balboni, S, Banerjee, S, Barberis, M, Barretina Ginesta, M, Baurain, J, Bignami, M, Bjorge, L, Blecharz, P, Bruchim, I, Capilna, M, Cerana, N, Cicchetti, A, Collins, D, Concin, N, D'Incalci, M, Davidson, B, de la Motte Rouge, T, De Iaco, P, Demirkiran, F, Denys, H, Doerk, T, Dorum, A, Ferrero, A, Fidalgo, A, Genuardi, M, Gladieff, L, Glasspool, R, Grimm, C, Gultekin, M, Hahnen, E, Hasenburg, A, Hegmane, A, Heinzelmann, V, Hogdall, E, Janavicius, R, Jarmalaite, S, Kalachand, R, Kaneva, R, Kilickap, S, Kocian, R, Kolencik, D, Kristeleit, R, Kryzhanivska, A, Leary, A, Lemley, B, Ligtenberg, M, Lopez-Guerrero, J, Lord, C, Avall-Lundqvist, E, Maenpaa, J, Mahner, S, Marme, F, Marth, C, Mcneish, I, Merkelbach-Bruse, S, Mourits, M, Normanno, N, Oaknin, A, Ojamaa, K, Papdimitriou, C, Penault-Llorca, F, Perrone, A, Pignata, S, Pikarsky, E, Rouleau, E, Rubio, M, Sapino, A, Schmalfeldt, B, Sehouli, J, Shapira, R, Steffensen, K, Sukhin, V, Syrios, J, Szallasi, Z, Taskiran, C, Terzic, M, Tischkowitz, M, Toth, I, Van de Vijver, K, Vardar, M, Wasag, B, Wimberger, P, and Witteveen, E

Subjects
Oncology, medicine.medical_specialty, MAINTENANCE THERAPY, CARCINOMA, Genetic counseling, BRCA, Delphi method, Carcinoma, Ovarian Epithelial, Poly(ADP-ribose) Polymerase Inhibitors, Gene mutation, Settore MED/03 - GENETICA MEDICA, BREAST, DOUBLE-BLIND, BRCA1/2, Internal medicine, Genetic predisposition, Medicine and Health Sciences, Tumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14], Medicine, Humans, BRCA2 MUTATIONS, OLAPARIB PLUS BEVACIZUMAB, Genetic testing, Ovarian Neoplasms, Ovarian Neoplasms/diagnosis, medicine.diagnostic_test, business.industry, MISMATCH REPAIR DEFICIENCY, PARP inhibition, mainstream genetic testing, Recombinational DNA Repair, Hematology, SOMATIC MUTATIONS, GERMLINE MUTATIONS, Poly(ADP-ribose) Polymerase Inhibitors/pharmacology, medicine.disease, FALLOPIAN-TUBE, Carcinoma, Ovarian Epithelial/genetics, ovarian cancer, homologous recombination deficiency, DNA mismatch repair, Female, business, Homologous recombination, Ovarian cancer, human activities, genetic counselling
Abstract

BACKGROUND: Homologous recombination repair (HRR) enables fault-free repair of double-stranded DNA breaks. HRR deficiency is predicted to occur in around half of high-grade serous ovarian carcinomas. Ovarian cancers harbouring HRR deficiency typically exhibit sensitivity to poly-ADP ribose polymerase inhibitors (PARPi). Current guidelines recommend a range of approaches for genetic testing to identify predictors of sensitivity to PARPi in ovarian cancer and to identify genetic predisposition. DESIGN: To establish a European-wide consensus for genetic testing (including the genetic care pathway), decision making and clinical management of patients with recently diagnosed advanced ovarian cancer, and the validity of biomarkers to predict the effectiveness of PARPi in the first-line setting. The collaborative European experts' consensus group consisted of a steering committee (n = 14) and contributors (n = 84). A (modified) Delphi process was used to establish consensus statements based on a systematic literature search, conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. RESULTS: A consensus was reached on 34 statements amongst 98 caregivers (including oncologists, pathologists, clinical geneticists, genetic researchers, and patient advocates). The statements concentrated on (i) the value of testing for BRCA1/2 mutations and HRR deficiency testing, including when and whom to test; (ii) the importance of developing new and better HRR deficiency tests; (iii) the importance of germline non-BRCA HRR and mismatch repair gene mutations for predicting familial risk, but not for predicting sensitivity to PARPi, in the first-line setting; (iv) who should be able to inform patients about genetic testing, and what training and education should these caregivers receive. CONCLUSION: These consensus recommendations, from a multidisciplinary panel of experts from across Europe, provide clear guidance on the use of BRCA and HRR deficiency testing for recently diagnosed patients with advanced ovarian cancer. ispartof: ANNALS OF ONCOLOGY vol:33 issue:3 pages:276-287 ispartof: location:England status: published

Published
2022

11. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆

Author

A. Oaknin, T.J. Bosse, C.L. Creutzberg, G. Giornelli, P. Harter, F. Joly, D. Lorusso, C. Marth, V. Makker, M.R. Mirza, J.A. Ledermann, N. Colombo, Oaknin, A, Bosse, T, Creutzberg, C, Giornelli, G, Harter, P, Joly, F, Lorusso, D, Marth, C, Makker, V, Mirza, M, Ledermann, J, and Colombo, N

Subjects
diagnosi, Oncology, ESMO Clinical Practice Guideline, treatment, endometrial cancer, follow-up, Hematology
Published
2022

12. 573P Role of CA125 in patients included in the DESKTOP III/ENGOT-ov20 trial

Author

F. Lecuru, J. Sehouli, I.B. Vergote, A. Reuss, J-M. Classe, P. Hillemanns, S. Greggi, M.R. Mirza, P.E. Brachet, P. Follana, N. Raban, A. Hasenburg, R. Zang, K. Lindemann, J-W. Kim, A. Poveda, F. Raspagliesi, C.A. Haslund, A. du Bois, and P. Harter

Subjects
Oncology, Hematology
Published
2022

13. 530P PRIMA/ENGOT-OV26/GOG-3012 study: Updated long-term PFS and safety

Author

A.J. Gonzalez Martin, B. Pothuri, I.B. Vergote, W. Graybill, M.R. Mirza, C. Mccormick, D. Lorusso, G. Freyer, F. Backes, K.H. Baumann, A. Redondo Sanchez, R.G. Moore, C. Vulsteke, R.E. O'Cearbhaill, I. Malinowska, L. Shtessel, N. Compton, and B.J. Monk

Subjects
Oncology, Hematology
Published
2022

14. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer Diagnosis, Treatment and Follow-up

Author

N. Colombo, C. Creutzberg, F. Amant, T. Bosse, A. González-Martín, J. Ledermann, C. Marth, R. Nout, D. Querleu, M.R. Mirza, C. Sessa, M. Abal, O. Altundag, Antoni van Leeuwenhoek, S. Banerjee, A. Casado, L.C. de Agustín, D. Cibula, J.-M. del Campo, G. Emons, F. Goffin, S. Greggi, C. Haie-Meder, D. Katsaros, V. Kesic, C. Kurzeder, S. Lax, F. Lécuru, T. Levy, D. Lorusso, J. Mäenpää, X. Matias-Guiu, P. Morice, H.W. Nijman, M. Powell, N. Reed, A. Rodolakis, H. Salvesen, J. Sehouli, A. Taylor, A. Westermann, A.G. Zeimet, Other departments, CCA -Cancer Center Amsterdam, Oncology, Colombo, N, Creutzberg, C, Amant, F, Bosse, T, González Martín, A, Ledermann, J, Marth, C, Nout, R, Querleu, D, Mirza, M, and Sessa, C

Subjects
medicine.medical_treatment, Alternative medicine, Scientific literature, Esgo, Medical Oncology, Body Mass Index, 0302 clinical medicine, FERTILITY-SPARING-MANAGEMENT, Societies, Medical, Adjuvant, Endometrial neoplasm, 030219 obstetrics & reproductive medicine, INDEPENDENT RISK-FACTOR, Gynaecological oncology, Radiology, Nuclear Medicine & Medical Imaging, Consensus conference, Obstetrics and Gynecology, PHASE-III TRIAL, Hematology, LYMPHVASCULAR SPACE INVOLVEMENT, UTERINE SEROUS CARCINOMA, POSTOPERATIVE RADIATION-THERAPY, Italy, Oncology, Diagnosis treatment, Radiology Nuclear Medicine and imaging, 030220 oncology & carcinogenesis, Practice Guidelines as Topic, ComputingMethodologies_DOCUMENTANDTEXTPROCESSING, WHOLE-ABDOMINAL-IRRADIATION, Female, Life Sciences & Biomedicine, medicine.medical_specialty, Practice guideline, Consensus, MEDLINE, Consensu, Uterine serous carcinoma, 03 medical and health sciences, medicine, Humans, Radiology, Nuclear Medicine and imaging, Endometrial neoplasms, Mass screening, Gynecology, Science & Technology, business.industry, Endometrial cancer, medicine.disease, Radiation therapy, Treatment, EXTERNAL-BEAM RADIOTHERAPY, CLINICAL STAGE-I, Family medicine, CLEAR-CELL, Surgery, business, Follow-Up Studies
Abstract

Supplemental digital content is available in the text., The first joint European Society for Medical Oncology (ESMO), European SocieTy for Radiotherapy & Oncology (ESTRO) and European Society of Gynaecological Oncology (ESGO) consensus conference on endometrial cancer was held on 11–13 December 2014 in Milan, Italy, and comprised a multidisciplinary panel of 40 leading experts in the management of endometrial cancer. Before the conference, the expert panel prepared three clinically-relevant questions about endometrial cancer relating to the following four areas: prevention and screening, surgery, adjuvant treatment and advanced and recurrent disease. All relevant scientific literature, as identified by the experts, was reviewed in advance. During the consensus conference, the panel developed recommendations for each specific question and a consensus was reached. Results of this consensus conference, together with a summary of evidence supporting each recommendation, are detailed in this article. All participants have approved this final article.

Published
2016

15. Mitomycin C and Haze

Author

Mujtaba A. Qazi, Irwin Y Cua, Jay S. Pepose, M.R. Mirza, and Saira A Choudhri

Subjects
Haze, Chemistry, Mitomycin C, Cancer research
Published
2004

16. Study of sugar beet growth pattern in Hamedan

Author

M.R. Mirzaei and M. Abdollahian-Noghabi

Subjects
GDD, growth index, Growth pattern, Leaf area index, Root yield, sowing date, Agriculture, Agriculture (General), S1-972
Abstract

The current study was carried out to examine sugar beet growth pattern in climatic conditions of Hamedan, Iran and to recognize the factors affecting its quantity and quality as well as the physiological indices. Two sowing date experiments were conducted on the basis of a Randomized Complete Block Design with four replications and 11 harvests. The plots were destructively sampled and the growth was analyzed by regression method on the basis of the variations of leaf area index, leaf dry weight and total dry weight which are the basis of growth analysis. Results revealed that the maximum crop growth rate of the earlier sowing date reached to 20.2 and 23.3 g.m-2.d-1 90 days after planting in 2002 and 2003, respectively. In the second sowing date, maximum crop growth rate reached to 29.5 and 25.0 g.m-2.d-1 110 and 96 days after planting in 2002 and 2003, respectively. Maximum leaf area index of the earlier sowing date was obtained about three months after planting approximately concurrent with the realization of maximum crop growth rate and reached to 2.5 in 2002 and to 2.6 in 2003, but it started to slowly decrease at later growth period. Relative growth rate was the highest at the early growth period and linearly decreased during growth period. Net assimilation rate firstly increased slowly, but as the leaves grew and shaded each other, it started to decrease. The highest root growth rate in the earlier sowing date reached to 10.1 and 20.0 g.m-2.d-1 94 and 92 days after planting in 2002 and 2003, respectively. The highest root growth rate in the second sowing date reached to 14.0 and 17.3 g.m-2.d-1 108 and 95 days after planting in 2002 and 2003, respectively. In total, root potential yield was considerably higher in the earlier than in the delayed sowing date under climatic conditions of Hamedan in both years. The sugar beet growth pattern-related physiological indices were greatly consistent with crop yield potential during growing season. Therefore, given the climate changes and global warming, sugar beet sowing in the earliest possible date in Hamedan is recommended in terms of physiological indices and yield.

Published
2012
Full Text
View/download PDF

17. Effect of verapamil on infarct size in acute myocardial infarction

Author

M.R. Mirza, Jamal Ahmad, and Siddiqui Ma

Subjects
medicine.medical_specialty, business.industry, Internal medicine, medicine, Cardiology, Verapamil, Myocardial infarction, Cardiology and Cardiovascular Medicine, Infarct size, medicine.disease, business, Molecular Biology, medicine.drug
Published
1986

Catalog

Books, media, physical & digital resources
See catalog results